Title: Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.
Authors: Dahl, Erika S; Buj, Raquel; Leon, Kelly E; Newell, Jordan M; Imamura, Yuka; Bitler, Benjamin G; Snyder, Nathaniel W; Aird, Katherine M
Published In Mol Cancer Res, (2019 08)
Abstract: Epithelial ovarian cancer (EOC) is the deadliest gynecologic cancer. High-grade serous carcinoma (HGSC) is the most frequently diagnosed and lethal histosubtype of EOC. A significant proportion of patients with HGSC relapse with chemoresistant disease. Therefore, there is an urgent need for novel therapeutic strategies for HGSC. Metabolic reprogramming is a hallmark of cancer cells, and targeting metabolism for cancer therapy may be beneficial. Here, we found that in comparison with normal fallopian tube epithelial cells, HGSC cells preferentially utilize glucose in the TCA cycle and not for aerobic glycolysis. This correlated with universally increased TCA cycle enzyme expression in HGSC cells under adherent conditions. HGSC disseminates as tumor cell spheroids within the peritoneal cavity. We found that wild-type isocitrate dehydrogenase I (IDH1) is the only TCA cycle enzyme upregulated in both adherent and spheroid conditions and is associated with reduced progression-free survival. IDH1 protein expression is also increased in patients with primary HGSC tumors. Pharmacologic inhibition or knockdown of IDH1 decreased proliferation of multiple HGSC cell lines by inducing senescence. Mechanistically, suppression of IDH1 increased the repressive histone mark H3K9me2 at multiple E2F target gene loci, which led to decreased expression of these genes. Altogether, these data suggest that increased IDH1 activity is an important metabolic adaptation in HGSC and that targeting wild-type IDH1 in HGSC alters the repressive histone epigenetic landscape to induce senescence. IMPLICATIONS: Inhibition of IDH1 may act as a novel therapeutic approach to alter both the metabolism and epigenetics of HGSC as a prosenescent therapy.
PubMed ID: 31110157
MeSH Terms: Apoptosis; Carcinoma, Ovarian Epithelial/genetics; Carcinoma, Ovarian Epithelial/metabolism; Carcinoma, Ovarian Epithelial/pathology*; Cell Proliferation; Cellular Senescence*; Cystadenocarcinoma, Serous/genetics; Cystadenocarcinoma, Serous/metabolism; Cystadenocarcinoma, Serous/pathology*; E2F Transcription Factors/genetics; E2F Transcription Factors/metabolism*; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic*; Histones/genetics; Histones/metabolism*; Humans; Isocitrate Dehydrogenase/genetics; Isocitrate Dehydrogenase/metabolism*; Neoplasm Grading; Survival Rate; Tumor Cells, Cultured